1 / 27

AFFINITY trial A ssessment o F F luoxet IN e I n s T roke recover Y

AFFINITY trial A ssessment o F F luoxet IN e I n s T roke recover Y. Co- principal investigators: Hackett M, Hankey GJ. Steering committee: Almeida O, Anderson CS, Beer C, Billot L, Dennis MS, Flicker L, Ford A, Jan S, Mead G. The burden of disability due to stroke.

jewel
Download Presentation

AFFINITY trial A ssessment o F F luoxet IN e I n s T roke recover Y

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AFFINITY trialAssessment oFFluoxetINe In sTroke recoverY Co- principal investigators: Hackett M, Hankey GJ. Steering committee: Almeida O, Anderson CS, Beer C, Billot L, Dennis MS, Flicker L, Ford A, Jan S, Mead G

  2. The burden of disability due to stroke • 4th leading cause of global disease burden • 16 million 1st-ever events • 51 million disability-adjusted life years • 5.7 million deaths • 50% of stroke survivors have long-term residual disability. • How can we improve recovery & reduce disability after stroke?

  3. Fluoxetine Animal studies suggest fluoxetine is effective ? directly improves motor function ? indirectly improves motivation and attention FLAME trial (Lancet Neurology, 2011;10:123-130) • Fluoxetine on Motor Rehabilitation after ischaemic stroke • RCT: 118 with acute ischaemic stroke & unilateral motor weakness • Intervention: 20 mg fluoxetine daily, 3 months vs. placebo

  4. FLAME trial: Modified Rankin score at 90 daysmRS 0-2: 26.3% fluoxetine vs 8.9% placeboOR = 3.8, 95% CI 1.2 to 10.7

  5. FLAME trial: Fugl Meyer Motor scores Adjusted mean Fugl-Meyer motor scale (FMMS) total scores at days 0, 30, and 90 Error bars represent 95% CI

  6. Rationale for a new trial FLAME results promising, however: • ? Internal validity (Random error) • only 57 pts assigned fluoexetine vs 56 placebo • Wide 95% CI of estimates (Independency OR = 3.8, 95% CI 1.2 to 10.7) • ? External validity (generalisability) We need to know: • Does fluoxetine really work and is it safe in elderly stroke pts? • Are the results generalisable to an Australian population? • Do the benefits persist after treatment has ceased?

  7. Adverse outcomes of SSRIs in older peopleBMJ 2011; 343: d4551 • Design: Population-based cohort study • Setting: 570 general practices in UK • Subjects: 60,746 people > 65 years with depression • Follow-up: 364 days median (91-1029 IQR) • Outcomes: Death, attempted suicide/self harm, stroke, MI, falls, fractures, upper GI bleeding, seizures, hyponatraemia • Analysis: Adjusted hazard ratios of outcomes with SSRIs vs when antidepressants not used.

  8. Adverse outcomes of SSRIs in older peopleBMJ 2011; 343: d4551 Outcome HR (95% CI) Absolute risk (%/yr) (Fluoxetine vs no antidepressant) • Mortality 1.54 (1.48-1.59) 4.4% (11.4% vs 7.0%) • Falls 1.66 (1.58-1.73) 2.1% (5.6% vs 3.5%) • Fractures 1.58 (1.48-1.68) 1.0% (2.8% vs 1.8%) • Stroke/TIA 1.17 (1.10-1.26) 0.4% (2.6% vs 2.2%) • MI 1.15 (1.04-1.27) 0.3% (1.3% vs 1.0%) • Attempted suicide/self-harm 2.16 (1.71-2.79) 0.3% (0.5% vs 0.2%) • Hyponatraemia 1.52 (1.33-1.75) 0.2% (0.5% vs 0.3%) • Upper GI bleed 1.27 (1.07-2.40) 0.1% (0.5% vs 0.4%) • Epilepsy/Seizures 1.83 (1.49-2.26) 0.1% (0.3% vs 0.2%)

  9. Assessment oFFluoxetine IN sTroke recoverY (AFFINITY) trial

  10. Primary aim 1 ◦ To determine if : fluoxetine, 20 mg, once daily, started 2-15 days after acute stroke, and continued for 6 months, improves recovery & functional ability.

  11. Secondary aims 2◦ To determine if fluoxetine… • Improves at 6 months • survival, • mood (PHQ-9), • cognitive function (TICSm), • HRQoL (SF-12), • Reduces at 6 months • fatigue (SF-36 vitality domain) • Is safe • Reduces the cost of health and social care • Has persisting effects at 12 months on: • functional ability, survival, mood, cognitive function, HRQoL, and fatigue

  12. Inclusion criteria • Male or female • ≥ 18 years of age • Clinical diagnosis of stroke; onset 2-15 days ago • Imaging consistent with ICH or ischaemic stroke • Neurological deficits at randomisation which are severe enough to warrant Rx (pt or carer perspective)

  13. Exclusion criteria • History of: • Epileptic seizures • Bipolar disorders • Drug overdose • Attempted suicide • Allergy to fluoxetine • Current or recent (<5/52) Rx with MAOI or pimozide • Current or recent (<1/12) depression requiring Rx with SSRI • Current Rx with other antidepressants unless agree to discontinue on randomisation • Unlikely to be contactable or available for follow-up over 12 months • Unlikely to survive 12 months (e.g. life-threatening illness) • SAH (except if 2◦ to ICH) • Pregnant or breast feeding, female of child bearing age not on adequate contraception • Hyponatraemia (sodium < 130 mmol/l) • Hepatic impairment (ALT < 120 U/L) • Renal impairment (Creatinine > 220 micromol/L)

  14. Trial recruitment and assessments: from the patients’ perspective Approached by clinician who checks inclusion and exclusion criteria and discusses rationale for fluoxetine vs placebo trial Receives patient information leaflet and verbal explanation Time to consider whether to take part Signs informed consent form (or next of kin) Information entered into trial database on-line (www.affinitytrial.org) and randomisation code assigned

  15. Randomisation Web-based, central randomisation service http://affinitytrial.org Rx allocation ratio 1:1 Minimisation algorithm: Time since stroke onset (2-8 vs 9-15 days) Presence of a motor deficit Presence of aphasia Probability of survival free of dependency at 6 months (0-15% vs 16-100%) (i.e. allocates each patient to the treatment group that leads to the least difference between the two groups with respect to these features)

  16. Intervention • Fluoxetine 20 mg/day or Placebo one/day • Oral • Double-blind • 6 months

  17. Adverse effects of newer antidepressants and suggested management.BMJ 2012; 344: d8300. Adverse effect Comment Management • Dizziness < 10% Check BP standing and lying; symptoms may improve over time; Decrease dose or change treatment. Ensure adequate fluid intake • Sedation Not common May be desirable; May improve over time. Change time of dosing and treatment • Dry mouth Probably dose related Tolerance may develop; change treatment; Sugarless gum or saliva substitutes • Sexual dysfunction Common Reduce dose, wait for improvement, switch to a different antidepressant, or consider sildenafil • Insomnia Common Try to distinguish from insomnia caused by depression Change time of dosing (earlier or later may help), improve sleep hygiene, try a different antidepressant, or short course of benzodiazepine, zopiclone, or low dose trazadone • Suicidal thoughts Age < 30 Review often (within a week of starting Rx and until no longer needed). No evidence that asking about suicide increases likelihood of self- harm. Prescribe small amounts of medication. • Anxiety Often when starting Rx Consider using a benzodiazepine for no longer than two weeks • Hyponatraemia A problem in the elderly Check sodium before and after starting treatment Consider changing to mirtazapine if it becomes problematic • Serotonin syndrome Confusion/agitation, Stop the antidepressant Autonomic instability,and Hydration, Rx of hyperthermia, and benzodiazepines Neuromuscular hyperactivity Consider cyproheptadine or chlorpromazine in severe cases • Discontinuation syndrome Decrease dose over four weeks. Warn the patient

  18. Management of depression Consider non-pharmacological treatments Advise an increase in social outlets and regular exercise Consider referral to a clinical psychologist. Clinical psychology can be accessed through the Medicare Better Access initiative free of charge to Australian residents & citizens for up to 12 sessions/year (http://www.health.gov.au/internet/main/publishing.nsf/Content/mental-ba-over Consider adding 10 mg of fluoxetine to the participant’s trial medications and increasing this further to 20 mg after 4-6 weeks if ineffective. This would mean that some participants would potentially be on 40 mg of fluoxetine a day. This dose has been shown to be effective and safe. Combination therapy (using >2 antidepressants simultaneously) should best be avoided in view of the risk of serotonergic syndrome, especially if using another SSRI. If choose to initiate possible combination therapy, use a non-serotonergic antidepressant such as reboxetine or one with less serotonergic activity such as mirtazapine Consider referral to a specialist psychiatrist

  19. Outcome measures • Primary: simplified modified Rankin score at 6 months • Stroke 2010; 41: 1048-50; Stroke 2011; 42: 2276-9; Stroke 2012; 43: 851-3. • Secondary • Adherence to medication • New clinical diagnosis of depression • Survival • Depression (PHQ 9; 9 questions) • Cognition (TICSm; 13 questions) • Fatigue (Vitality score of SF-36; 4 questions) • Resource use (3 questions) Optional • Overall health status: Stroke impact score (59 items, 8 domains) • Health-related quality of life (SF 12; 12 questions)

  20. Sample size calculations • Expect % of independent participants (mRS 0-2) in intervention group to: • increase by 7.5% absolute percentage points (from 50% to 57.5%) • increase by 15 relative percentage points, • odds ratio of 1.35 • (cf. FLAME: OR = 3.8, 95%: CI 1.2 to 10.7)

  21. 1,580 patients Informed consent and trial specific screen and baseline assessment Central randomisation 2 to 15 days post-stroke Intervention group (n=790) Control group (n=790) 1 month on-intervention assessment 3 month on-intervention assessment and dispensing End of 6-month intervention assessment 6-month off-intervention (12 month) assessment Trial design:Flow of participants and assessments

  22. Collaborators (UK FOCUS)Prof Martin Dennis Dr Gillian Mead • Larger, similar trial • FOCUS pilot phase • Funded by The Stroke Association • Protocol funded by NIHR Stroke Research Network • FOCUS main phase • Funding application to NIHR HTA • Planned prospective meta-analysis

  23. AFFINITY/FOCUS joint analyses FOCUS aims to recruit 3000 If we complete both FOCUS and AFFINITY and enrol 4500 patients we could reliably detect a 4.4% absolute increase in mRS 0-2.

  24. We welcome interested collaborators

  25. Disability at end of Rx

  26. Disability at end of Rx, by depression or not at randomisation

More Related